DE69735496T2 - Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert - Google Patents

Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert Download PDF

Info

Publication number
DE69735496T2
DE69735496T2 DE69735496T DE69735496T DE69735496T2 DE 69735496 T2 DE69735496 T2 DE 69735496T2 DE 69735496 T DE69735496 T DE 69735496T DE 69735496 T DE69735496 T DE 69735496T DE 69735496 T2 DE69735496 T2 DE 69735496T2
Authority
DE
Germany
Prior art keywords
protein
dna
cells
intestinal
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69735496T
Other languages
German (de)
English (en)
Other versions
DE69735496D1 (de
Inventor
Michael San Francisco GERMAN
D. Ira Kentfield GOLDFINE
S. Stephen Berkeley ROTHMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California, San Diego
Original Assignee
University of California
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California, San Diego filed Critical University of California
Publication of DE69735496D1 publication Critical patent/DE69735496D1/de
Application granted granted Critical
Publication of DE69735496T2 publication Critical patent/DE69735496T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69735496T 1996-09-19 1997-09-18 Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert Expired - Fee Related DE69735496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/717,084 US6225290B1 (en) 1996-09-19 1996-09-19 Systemic gene therapy by intestinal cell transformation
US717084 1996-09-19
PCT/US1997/016523 WO1998011779A1 (en) 1996-09-19 1997-09-18 Delivery of therapeutic gene products by intestinal cell expression

Publications (2)

Publication Number Publication Date
DE69735496D1 DE69735496D1 (de) 2006-05-11
DE69735496T2 true DE69735496T2 (de) 2006-09-21

Family

ID=24880656

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735496T Expired - Fee Related DE69735496T2 (de) 1996-09-19 1997-09-18 Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert

Country Status (10)

Country Link
US (4) US6225290B1 (enExample)
EP (1) EP0939590B1 (enExample)
JP (1) JP2001502303A (enExample)
AT (1) ATE320186T1 (enExample)
AU (1) AU729457B2 (enExample)
CA (1) CA2264744A1 (enExample)
DE (1) DE69735496T2 (enExample)
DK (1) DK0939590T3 (enExample)
ES (1) ES2256896T3 (enExample)
WO (1) WO1998011779A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
PL345241A1 (en) * 1998-05-06 2001-12-03 Upjohn Co Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
JPH11335269A (ja) 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
CA2364417C (en) * 1999-02-19 2013-11-05 Matthew John During Peroral gene therapy of diabetes and obesity
EP1889914A1 (en) * 1999-02-19 2008-02-20 Engene, Inc. Compositions for gene therapy of diabetes
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
NZ514620A (en) * 1999-03-04 2004-04-30 Ppl Therapeutics Scotland Ltd Genetic modification of somatic cells and uses thereof
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
CN102151337B (zh) * 2000-03-13 2014-03-12 恩根尼公司 调节消化道蛋白表达的组合物和方法
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
GB0010630D0 (en) * 2000-05-04 2000-06-21 Univ Wales Medicine Sequence
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
US6774223B2 (en) 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20020151068A1 (en) * 2001-01-03 2002-10-17 Board Of Regents, The University Of Texas System Compositions and methods for the diagnosis and treatment of organophosphate toxicity
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
EP1383929A4 (en) * 2001-04-04 2006-06-07 Neurome Inc GENES EXPRESSED IN DARMEPITHELIAL CELLS AND PEYERS 'PATCH M-CELLS
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
EP1404713A4 (en) * 2001-05-24 2004-09-22 Human Dna Technology Inc NEW KERATINOCYTE GROWTH FACTOR 2 ANALOG IN HAIR FOLLICULES
AU2002365188A1 (en) * 2001-11-07 2003-07-30 Musc Foundation For Research Development Nucleic acid delivery and expression
US20030135195A1 (en) * 2002-01-16 2003-07-17 Oscar Jimenez Highly lubricious hydrophilic coating utilizing dendrimers
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
AU2003265228A1 (en) * 2002-03-12 2003-12-22 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
AU2003273206B2 (en) * 2002-05-31 2009-08-20 Children's Hospital Medical Center Method, composition and kit for antigenic binding of Norwalk-Like viruses
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
MXPA05004163A (es) * 2002-10-24 2005-10-05 Biogen Idec Inc Vector de locus de alta expresion basado en locus del gen de la cadena pesada de la ferritina.
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2005032574A1 (en) * 2003-10-03 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20090286962A1 (en) * 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
EP2225263A1 (en) * 2007-11-26 2010-09-08 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US8703152B2 (en) 2008-06-03 2014-04-22 University Of Rochester Methods of treating inflammatory intestinal disease and managing symptoms thereof
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100068266A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo-modifiable multiple-release state final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
CN107043408B (zh) 2009-06-09 2021-02-09 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
US20160160229A1 (en) * 2014-12-09 2016-06-09 THC Farmaceuticals, Inc. Methods of producing antibody-rich cannabis and honeysuckle plants
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
WO2021119585A1 (en) * 2019-12-13 2021-06-17 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
MX2022007756A (es) * 2019-12-20 2022-09-27 Translate Bio Inc Suministro rectal de arn mensajero.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
WO1990005787A1 (en) 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
WO1994016057A1 (en) * 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Enhancer sequence for modulating expression in epithelial cells
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
WO1994029471A1 (en) 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US5681744A (en) * 1995-03-17 1997-10-28 Greenstein; Robert J. Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
EP0831771A2 (en) 1995-06-07 1998-04-01 Alza Corporation Oral delivery of gene constructs
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation

Also Published As

Publication number Publication date
US20020039574A1 (en) 2002-04-04
JP2001502303A (ja) 2001-02-20
EP0939590A1 (en) 1999-09-08
EP0939590B1 (en) 2006-03-15
US6225290B1 (en) 2001-05-01
US20050026863A1 (en) 2005-02-03
CA2264744A1 (en) 1998-03-26
US6258789B1 (en) 2001-07-10
AU4422197A (en) 1998-04-14
EP0939590A4 (en) 2002-09-04
US6831070B2 (en) 2004-12-14
ATE320186T1 (de) 2006-04-15
DK0939590T3 (da) 2006-07-24
ES2256896T3 (es) 2006-07-16
DE69735496D1 (de) 2006-05-11
AU729457B2 (en) 2001-02-01
WO1998011779A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
DE69233013T2 (de) Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US6258789B1 (en) Delivery of gene products by intestinal cell expression
DE69719360T2 (de) Zusammensetzungen und methoden zur steigerung der darmfunktion
DE69737266T2 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
KR102052204B1 (ko) 신규 재조합 엑소좀 및 그의 용도
DE60023906T2 (de) Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
DE69521880T2 (de) Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
DE69631544T2 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
JP2828250B2 (ja) 真性糖尿病の治療
DE69807679T2 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
DE60121355T2 (de) Absorptionsverbesserer
LU84546A1 (de) Verwendung von peptiden als medikamente
CN102151337B (zh) 调节消化道蛋白表达的组合物和方法
DE60037189T2 (de) Rekombinante, natrium-jodid symporter-kodierende adenoviren
DE10035156A1 (de) Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
DE60014856T2 (de) Zusammensetzungen zur modulierung der schleimsekretion
DE69129267T2 (de) Methode zur behandlung intestinaler krankheiten
DE69901536T2 (de) Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
DE69735533T2 (de) Lösliche Polypeptide bestehend aus der ersten Coiled coil Domäne aus Mensch- und Maus-Epimorphin
DE69330483T2 (de) Hepatom-behandlung mit somatostatin-analogen
AU744279B2 (en) Protein delivery by secretory gland expression
EP0707655B1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
DE69938130T2 (de) Neue peptide
DE60226343T2 (de) Zur glucoseregulierten produktion von menschlichem insulin in somatischen zelllinien geeignete nukleinsäurekonstrukte

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee